70,361 Shares in DaVita Inc. (NYSE:DVA) Purchased by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd purchased a new position in DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 70,361 shares of the company's stock, valued at approximately $10,763,000. AustralianSuper Pty Ltd owned about 0.09% of DaVita as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. UMB Bank n.a. raised its stake in DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Copia Wealth Management purchased a new stake in DaVita in the fourth quarter valued at approximately $30,000. Coppell Advisory Solutions LLC grew its position in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after acquiring an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan bought a new position in DaVita during the fourth quarter valued at approximately $55,000. Finally, GeoWealth Management LLC grew its position in DaVita by 30.6% during the fourth quarter. GeoWealth Management LLC now owns 525 shares of the company's stock valued at $79,000 after acquiring an additional 123 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on DVA. Truist Financial cut their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday, May 19th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $164.50.

DaVita Price Performance

Shares of NYSE:DVA opened at $141.13 on Friday. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60. The business has a 50-day simple moving average of $140.11 and a two-hundred day simple moving average of $148.57. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. The firm has a market cap of $10.66 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 0.97 and a beta of 1.11.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 176.11% and a net margin of 6.63%. DaVita's revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.26 EPS. On average, analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.